Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
DNA single-strand and double-strand breaks produced by doxorubicin and two anthracycline derivatives (4-demethoxy-daunorubicin and 4'-deoxy-4'-iododoxorubicin) were measured in doxorubicin-sensitive and -resistant P388 leukemia cell lines, using filter elution methods, and compared with cellular drug accumulation to account for major differences in their cytotoxic activities and cross-resistance. The increased cytotoxic potency of the two derivatives reflects at least in part the enhanced drug accumulation by cells that results from their increased lipophilicity. However, the level of protein-linked DNA breaks was not directly related to cellular accumulation of drug analogues. It is possible that enhanced cytotoxicity may also be the consequence of the greatly enhanced ability of analogues to cause DNA strand breaks. The resistant line showed only a modest degree of resistance to both anthracycline derivatives compared with the high degree of resistance to doxorubicin. Although for all the anthracyclines tested drug accumulation was reduced in the resistant line, this did not correlate with the degree of resistance. A differential sensitivity of resistant and parental cell lines to DNA cleavage activity was consistently found for all three drugs tested. However, in contrast to a lack of effect of doxorubicin, the derivatives caused appreciable DNA strand breakage in resistant cells. The enhanced ability of these analogues to break DNA in resistant cells is consistent with the slight cross-resistance with doxorubicin. DNA double-strand breaks produced in isolated nuclei from these cells paralleled the pattern found in whole cells, thus indicating that a nuclear alteration, presumably involving DNA topoisomerases, is associated with anthracycline resistance. Our findings strongly support the hypothesis that anthracycline resistance in these cell variants may be mediated by multiple mechanisms, involving alterations of plasma membrane and changes of nuclear enzymatic activities responsible for DNA strand breaks.
Capranico
G
G
Riva
A
A
Tinelli
S
S
Dasdia
T
T
Zunino
F
F
D000818:Animals; D000903:Antibiotics, Antineoplastic; D002460:Cell Line; D002467:Cell Nucleus / Q000187:drug effects; D004247:DNA / Q000187:drug effects*; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015255:Idarubicin; D007941:Leukemia P388 / Q000188:drug therapy / Q000235:genetics*; D007942:Leukemia, Experimental / Q000235:genetics*; D051379:Mice; D009279:Naphthacenes / Q000627:therapeutic use; D009690:Nucleic Acid Conformation / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C053044:4'-deoxy-4'-iododoxorubicin; D004317:Doxorubicin; D004247:DNA; D015255:Idarubicin; D003630:Daunorubicin